Cargando…
The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives
Down syndrome (DS), also known as trisomy 21, is a genetic disorder caused by triplication of Chromosome 21. Gene triplication may compromise different body functions but invariably impairs intellectual abilities starting from infancy. Moreover, after the fourth decade of life people with DS are lik...
Autores principales: | Stagni, Fiorenza, Bartesaghi, Renata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130961/ https://www.ncbi.nlm.nih.gov/pubmed/35634470 http://dx.doi.org/10.3389/fncel.2022.903729 |
Ejemplares similares
-
Timing of therapies for Down syndrome: the sooner, the better
por: Stagni, Fiorenza, et al.
Publicado: (2015) -
Targeting APP/AICD in Down syndrome
por: Guidi, Sandra, et al.
Publicado: (2017) -
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome
por: Giacomini, Andrea, et al.
Publicado: (2015) -
Impaired Brain Mitochondrial Bioenergetics in the Ts65Dn Mouse Model of Down Syndrome Is Restored by Neonatal Treatment with the Polyphenol 7,8-Dihydroxyflavone
por: Valenti, Daniela, et al.
Publicado: (2021) -
The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome
por: Stagni, Fiorenza, et al.
Publicado: (2021)